In another phase III trial, cholinesterase inhibitors, including galantamine, donepezil, and rivastigmine, were observed to have a lesser memory-enhancing effect, and side effects, including vomiting, nausea, diarrhea, sleeplessness, muscular spasm, loss of fatigue, and loss of hunger, were observed in severe AD subjects (https://clinicaltrials.gov/ct2/show/NCT02035982). The gene discussed is BCHE; the disease is Alzheimer disease.